Reinhard Dummer

University Hospital of Zurich
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.

Year:

2025

Purpose: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100–positive cells, in metastatic uveal melanoma. Experimental Design: HLA-A*02:01–positive patients with unresectable or metastatic uveal melanoma enrolled in three clinical trials (IMCgp100-01, IMCgp100-102, and IMCgp100-202) who received ≥1 dose of tebentafusp were included. Safety data were pooled to evaluate the profile, onset, and management of treatment-related adverse events (TRAE). Adverse events of special interest included cytokine release syndrome (CRS), acute skin reactions (ASR), and liver function test elevations. Primary prophylaxis with medications was not permitted. Results: Among 410 tebentafusp-treated patients, the most common TRAE were pyrexia (77%), pruritus (71%), and chills (53%). Most patients experienced CRS (88%), almost always mild (grade 1, 19%) to moderate (grade 2, 67%) in severity, with only 2% experiencing grade 3 ( n = 6) or 4 ( n = 1) CRS. Additionally, 92% had at least one ASR, primarily pruritus and rash, with 21% having a grade 3 event. Onset of CRS and ASR was within 1 to 2 days of infusion and generally reversible with standard interventions. Elevated liver function tests were generally mild and resolved without intervention. Most TRAE occurred following the first few infusions and diminished in frequency and severity with repeated dosing; no cumulative TRAE were detected. Discontinuations due to TRAE were rare (2%); there were no treatment-related deaths. Conclusions: TRAE were consistent with tebentafusp’s mechanism of action, mostly occurred during dose escalation, and were predictable, reversible, and manageable with appropriate surveillance and intervention.

Year:

2025

Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies ( N = 410). A, Weekly incidence of TRAE during the acute phase (1–12 weeks). B, Long-term incidence of TRAE in 3-month intervals up to 30 months, which can be broken down into acute (months 1–3), intermediate (months 4–12), and late phases (>12 months). *Rash, LFT, and MRAE are composite terms for a list of related AE of any grade (Supplementary Table S1).

Year:

2025

Frequency of AESI by maximum grade and kinetics of onset and resolution of AESI. A, Frequency of each AESI by grade. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410). B and C, Median time to ( A ) onset from the start of the first dose or ( B ) resolution from the start of AESI for CRS, ASR, and LFT elevations. The peak of each curve shows the proportion of patients who developed that AESI. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410).

Year:

2025

Landmark OS for corticosteroid use within the first 30 days of the first tebentafusp dose. Kaplan–Meier plot of inverse probability of treatment–weighted OS (ATE weights) by corticosteroid use within the first 30 days of the first tebentafusp dose, landmarked at day 30. HR (95% confidence interval), 1.09 (0.67–1.76). ATE, average treatment effects.

Year:

2025

S2: HPLC analysis of STO13881 and nNeocuproine showed overlapping profiles and confirmed STO13881 to be neocuproine (purchased from Sigma-Aldrich, Switzerland). High-performance liquid chromatography (HPLC) analysis was performed using the Zuürich functional genomic center.

Year:

2025

Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mutation as well as the ratio of neocuproine normalized to the MEKi response.

Year:

2025

In cutaneous T‐cell lymphoma (CTCL), chronic pruritus affects up to 94% of patients as a leading factor reducing quality of life (QoL). Traditional antipruritic medication does not show sufficient relief. Partly due to a lack of therapeutic options, pruritus is rarely assessed in a standardized manner within routine clinical practice. In this cross‐sectional, single‐institution study, we characterized CTCL‐associated pruritus including perception, dynamics, and modifying factors. QoL was evaluated with the Dermatology Life Quality Index (DLQI) and EORTC core quality of life questionnaire (QLQ‐C30). Patients with early‐stage Mycosis fungoides (MF, n = 16), late‐stage MF ( n = 10) and Sézary syndrome (SS, n = 10), treated at the University Hospital of Zurich, completed all three questionnaires. 80.5% ( n = 29/36) patients reported disease‐associated pruritus worsening with stress (51.7%, n = 15/29), scratching (37.9%, n = 11/29), and sweating or exercise (31.0%, n = 9/29). DLQI was associated with CTCL‐specific skin involvement (modified severity‐weighted assessment tool, mSWAT) (ρ = 0.44, p < 0.01), worst experienced pruritus ( ρ = 0.42, p = 0.04) and current perceived pruritus ( ρ = 0.60, p < 0.01). Summarizing those three factors in a Pruritus‐Score correlated strongly with DLQI ( ρ = 0.71, p < 0.01), QLQ‐C30 global health status ( ρ = −0.71, p < 0.01) as well as fatigue ( ρ = 0.50, p = 0.02). Our results confirm the relevance of pruritus in CTCL. The Pruritus‐Score outperforms solely assessment of present pruritus in identifying patients who might experience related impairments in QoL. It quantifies this complex symptom in three factors that can be collected in clinical practice. This Pruritus‐Score can support consideration of pharmaceutical and non‐pharmaceutical approaches aimed at addressing reductions in quality of life and associated symptoms such as fatigue.

Year:

2025

PFS in ( A ) part I/run-in and ( B ) part II. A, Kaplan–Meier analysis of PFS with encorafenib plus binimetinib in naïve and pretreated patients in the FAS population. B, Kaplan–Meier analysis of PFS in the encorafenib plus binimetinib and ribociclib, encorafenib plus binimetinib and capmatinib, and encorafenib plus binimetinib and buparlisib arms.

Year:

2025

Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study, assessed encorafenib plus binimetinib combined with a third targeted agent after tumor progression on encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. Patients and Methods: Adults with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma who were BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) treatment–naïve or pretreated received encorafenib plus binimetinib (part I/run-in). Based on the genomic testing at disease progression following encorafenib plus binimetinib, patients were assigned to one of four treatment arms to receive encorafenib plus binimetinib with an appropriate molecularly targeted agent (ribociclib, infigratinib, capmatinib, or buparlisib; part II). The primary endpoint was best overall response; safety, biomarkers, pharmacokinetics, and other efficacy endpoints were also assessed. Results: In part I/run-in, 75 BRAFi/MEKi-naïve patients and 83 BRAFi/MEKi-pretreated patients were treated; in part II, 58 patients were treated (ribociclib, n = 38; infigratinib, n = 1; capmatinib, n = 13; buparlisib, n = 6). The overall confirmed response rate was 73.3% [95% confidence interval (CI), 61.9–82.9] in BRAFi/MEKi-naïve patients, 25.3% (95% CI, 16.4–36.0) in pretreated patients, 2.6% (95% CI, 0.1–13.8) in the ribociclib arm, and 0% in the other three arms. Adverse events were manageable and consistent with the known safety profile of each drug. Conclusions: LOGIC 2 supports the use of encorafenib plus binimetinib for treatment-naïve and previously treated, locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. However, adding a third targeted agent following disease progression did not show meaningful efficacy; further research is needed to identify other therapeutic targets to circumvent resistance.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (61)

caroline robert

- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

Université de Paris Faculté de Santé

FRANCE
View details

Govind Warrier

Assistant Professor of Oncology

Johns Hopkins University

UNITED STATES
View details

Georgina V. Long

University of Sydney

AUSTRALIA
View details

Pål Johansen

University of Zurich

SWITZERLAND
View details

Joseph J. Sacco

Senior Lecturer Clinical

University of Liverpool

UNITED KINGDOM
View details

Andrea Bileck

Senior Scientist

Universität Wien

AUSTRIA
View details

Jessica C. Hassel

Heidelberg University

GERMANY
View details

L. V. Maul

-

SWITZERLAND
View details

Takami Sato

Professor

Thomas Jefferson University

UNITED STATES
View details

Mitchell Levesque

-

SWITZERLAND
View details

Ossia M Eichhoff

Senior Scientist

University Hospital of Zurich

SWITZERLAND
View details

Patricia Bortel

University Assistant

Universität Wien

AUSTRIA
View details

Stefan Kasper

Professor of Medical Oncology

-

GERMANY
View details

Verena Paulitschke

Assoc.Prof. Dr./ PhD

Medical University of Vienna

AUSTRIA
View details

Alaa Othman

Metabolomics Unit Head

ETH Zurich

SWITZERLAND
View details

Christopher Gerner

Full Professor

-

AUSTRIA
View details

Michael Krauthammer

Professor

University of Zurich

SWITZERLAND
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Anna Spreafico

University Health Network

CANADA
View details

Nicola Zamboni

Adj. Prof

ETH Zürich

SWITZERLAND
View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Marcus Butler

University Health Network

CANADA
View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES
View details

Wilson H Miller Jr

McGill University

CANADA
View details

Zsolt Balázs

Senior Researcher

University Hospital of Zurich

SWITZERLAND
View details

Cornelia Mauch

Assistant professor

university hospital of the ruhr university bochum

GERMANY
View details

Anthony M. Joshua

Head of Department

University Health Network

CANADA
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

F. Dimitriou

Attending Physician, Head of Skin Cancer Center

University Hospital of Bern

SWITZERLAND
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Noor Shoushtari

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Christoph Hoeller

Associate Professor, Head of Skin Cancer Center

Medical University of Vienna

AUSTRIA
View details

Paul Nathan

University College London

UNITED KINGDOM
View details

Lars French

Professor of Precision and Translational Dermatology

Ludwig-Maximilians-Universität München

GERMANY
View details

Georg Stary

Attending, Group Leader

Medical University of Vienna

AUSTRIA
View details

Ramon Staeger

University Hospital of Zurich

SWITZERLAND
View details

Berend Snijder

Assistant Professor

ETH Zürich

SWITZERLAND
View details

Ryan Sullivan

Harvard University

UNITED STATES
View details

Sebastian Ochsenreither

Charité - Universitätsmedizin Berlin

GERMANY
View details

Elena Garralda

Director

-

SPAIN
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Leitner

Senior Scientist / Principal Investigator

ETH Zürich

SWITZERLAND
View details

I. Steiner

-

AUSTRIA
View details

Hubert Hackl

Associate Professor

Medical University of Innsbruck

AUSTRIA
View details

Lucie Heinzerling

University Hospital

GERMANY
View details

Shahneen Sandhu

-

AUSTRALIA
View details

Zlatko Trajanoski

Professor

Medical University of Innsbruck

AUSTRIA
View details

Martin Schuler

Professor of Medicine

Universität Duisburg-Essen

GERMANY
View details

Piotr Rutkowski

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

Ludovic Gillet

Lecturer

ETH Zürich

SWITZERLAND
View details

Martin Distel

Associate Professor

University of Utah

UNITED STATES
View details

Mark Middleton

University of Oxford

UNITED KINGDOM
View details

Andreas Dominik Braun

Professor for Digital and Molecular Dermatopathology

University of Lübeck

GERMANY
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

Adelheid Elbe-Bürger

Lab head

Medical University of Vienna

AUSTRIA
View details

Phil Cheng

Bioinformatician

University Hospital of Geneva

SWITZERLAND
View details

Shailender Bhatia

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

W. Weninger

Professor and Chair

Medical University of Vienna

AUSTRIA
View details

Jason J. Luke

-

UNITED STATES
View details

Ines Pires da Silva

Medical Oncologist

University of Sydney

AUSTRALIA
View details